STE:NYSESTERIS plc (Ireland) Analysis

STERIS is trading around $216, just above its 20‑day SMA (≈$213) but below the 50‑day and 200‑day averages, indicating a short‑term bearish bias despite a bullish MACD crossover and a neutral RSI near 50. Volume is increasing and the 30‑day volatility is high at roughly 28%, while beta is modest (overvalued with limited upside (~19% upside to the DCF target) and a downside risk of over 50% to intrinsic value.
Fundamentally, STE posted $5.94 B in revenue with 7.3% YoY growth, solid gross (44%) and operating (20%) margins, and a healthy free cash flow generation of $587 M. EPS is expected to rise from $7.94 trailing to $12.1 forward, and the forward PE of ~18 is well below the industry average of 27, supporting a growth narrative. The company pays a modest 1.17% dividend with a 31% payout ratio, and a $1 B share‑repurchase program underscores confidence. Analysts collectively rate the stock as a “buy,” reflecting confidence in its medium‑term earnings trajectory.